| Literature DB >> 29985542 |
Shoujun Zhu1, Zhubin Hu2, Rui Tian1,3, Bryant C Yung1, Qinglai Yang4, Su Zhao4, Dale O Kiesewetter1, Gang Niu1, Haitao Sun2, Alexander L Antaris5, Xiaoyuan Chen1.
Abstract
The significantly reduced tissue autofluorescence and scattering in the NIR-II region (1000-1700 nm) opens many exciting avenues for detailed investigation of biological processes in vivo. However, the existing NIR-II fluorescent agents, including many molecular dyes and inorganic nanomaterials, are primarily focused on complicated synthesis routes and unknown immunogenic responses with limited potential for clinical translation. Herein, the >1000 nm tail emission of conventional biocompatible NIR cyanine dyes with emission peaks at 700-900 nm is systematically investigated, and a type of bright dye for NIR-II imaging with high potential for accelerating clinical translation is identified. The asymmetry of the π domain in the S1 state of NIR cyanine dyes is proven to result in a twisted intramolecular charge-transfer process and NIR-II emission, establishing a general rule to guide future NIR-I/II fluorophore synthesis. The screened NIR dyes are identified to possess a bright emission tail in the NIR-II region along with high quantum yield, high molar-extinction coefficient, rapid fecal excretion, and functional groups amenable for bioconjugation. As a result, NIR cyanine dyes can be used for NIR-II imaging to afford superior contrast and real-time imaging of several biological models, facilitating the translation of NIR-II bioimaging to clinical theranostic applications.Entities:
Keywords: NIR-I fluorophores; NIR-II imaging; cyanine dye; emission tail; tumor imaging
Year: 2018 PMID: 29985542 DOI: 10.1002/adma.201802546
Source DB: PubMed Journal: Adv Mater ISSN: 0935-9648 Impact factor: 30.849